
"I am glad that taking part in a trial might help others on their own cancer journey.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a new drug called LY2495655 to treat muscle loss and weakness in people with pancreatic cancer that has spread into nearby tissue () or to another part of the body.
People with advanced cancer often have loss of muscle and muscle weakness. Currently there is no treatment for this. This trial is looking at a drug called LY2495655 to help stop muscle loss and weakness.
LY2495655 works by blocking a substance (protein) called myostatin. Myostatin controls muscle growth in the body. By blocking it, the researchers hope LY2495655 will help control muscle loss and weakness.
The researchers will be looking at LY2495655 in combination with chemotherapy for advanced pancreatic cancer. The trial drug will not be treating the cancer itself.
The aims of this trial are to find out
You may be able to enter this trial if you
You cannot enter this trial if
This is a phase 2 trial. It will recruit 120 people from different countries around the world. It is a randomised trial. The people taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in. And neither of you will know which group you are in either. This is called a double blind trial.
The 2 groups are
Your doctor will talk to you about which chemotherapy is best for you and how you have it.
You have LY2495655 or the dummy drug as an injection into a vein. You have LY2495655 or the dummy drug every 2 weeks while you continue to have your chemotherapy. As long as you don’t have bad side effects, you can carry on having LY2495655 for as long as it helps you, even if you stop your chemotherapy.
The trial team will ask you to fill out a questionnaire before you start treatment, during your treatment and then after you finish treatment. The questionnaire will ask about side effects and how you’ve been feeling. This is called a quality of life study.
The researchers will also take a blood sample to find out how LY2495655 works in your body and how your genes may affect the way you respond to it and the side effects you may have. You must agree to this if you want to take part in this trial.
You see the doctor to have some tests before taking part in the trial. These tests include
During treatment you see the doctor regularly for the same tests. You have LY2495655 or the dummy drug every 2 weeks.
Your doctor will talk to you about when they want to see you after you finish treatment.
LY2495655 is a new drug and there may side effects we don’t know about. The known side effects include
Your doctor will talk to you about the possible side effects of LY2495655 and the chemotherapy you have before you agree to take part in this trial.
We have more information about chemotherapy for advanced pancreatic cancer and the side effects of treatment on our chemotherapy for pancreatic cancer page.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Kenneth Fearon
Eli Lilly and Company Limited
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)
Freephone 0808 800 4040
"I am glad that taking part in a trial might help others on their own cancer journey.”